22 - CLAP

1114. Demissie K, Marcella SW, Breckenridge MB, Rhoads GG. Maternal asthma and transient tachypnea ofthe newborn. Pediatrics. 1998 Jul;102(1 Pt 1):84-90.1115. Fagiani G, Figueroa R, Cerezo R. Uso de furosemida en taquipnea transitoria del recién nacido. GuatPediatr 1988;10:271116. Ghidini A, Hicks C, Lapinski RH, Lockwood CJ. Morbidity in the preterm infant with mature lungindices. Am J Perinatol. 1997 Feb;14(2):75-8.1117. Greenough A, Lagercrantz H. Catecholamine abnormalities in transient tachypnoea of the prematurenewborn. J Perinat Med. 1992;20(3):223-6.1118. Gross TL, Sokol RJ, Kwong MS, Wilson M, Kuhnert PM. Transient tachypnea of the newborn: therelationship to preterm delivery and significant neonatal morbidity. Am J Obstet Gynecol. 1983 Jun1;146(3):236-41.1119. Halliday HL, McClure G, Reid MM.Transient tachypnoea of the newborn: two distinct clinical entities?Arch Dis Child. 1981 May;56(5):322-5.1120. Heaf DP, Belik J, Spitzer AR, Gewitz MH, Fox WW. Changes in pulmonary function during the diureticphase of respiratory distress syndrome. J Pediatr. 1982 Jul;101(1):103-7.1121. Patel DM, Donovan EF, Keenan WJ. Transient respiratory difficulty following cesarian delivery. BiolNeonate. 1983;43(3-4):146-51.1122. Rawlings JS, Smith FR. Transient tachypnea of the newborn. An analysis of neonatal and obstetric riskfactors. Am J Dis Child. 1984 Sep;138(9):869-71.1123. Ross BS, Pollak A, Oh W.The pharmacologic effects of furosemide therapy in the low-birth-weightinfant. J Pediatr. 1978 Jan;92(1):149-52.1124. Tudehope DI, Smyth MH. Is transient tachypnoea of the newborn always a benign disease? Report of 6babies requiring mechanical ventilation. Aust Paediatr J. 1979 Sep;15(3):160-5.Apnea1125. Aggarwal R, Singhal A, Deorari AK, PaulVK.Apnea in the newborn. Indian J Pediatr. 2001 Oct;68(10):959-62.1126. Al-Aif S, Alvaro R, Manfreda J, Kwiatkowski K, Cates D, Rigatto H. Inhalation of low (0.5%-1.5%)CO2 as a potential treatment for apnea of prematurity. Semin Perinatol. 2001 Apr;25(2):100-6.1127. Bhatia J. Current options in the management of apnea of prematurity. Clin Pediatr (Phila). 2000Jun;39(6):327-36.1128. Bhatt-Mehta V, Schumacher RE.Treatment of apnea of prematurity. Paediatr Drugs. 2003;5(3):195-210.1129. Carnielli VP, Verlato G, Benini F, et al. Metabolic and respiratory effects of theophylline in the preterminfant. Arch Dis Child Fetal Neonatal Ed. 2000 Jul;83(1):F39-43.1130. Curzi-Dascalova L, Bloch J, Vecchierini M, Bedu A, Vignolo P. Physiological parameters evaluationfollowing apnea in healthy premature infants. Biol Neonate. 2000 May;77(4):203-11.1131. Dutta S. High-flow nasal cannula versus nasal continuous positive airway pressure in the management ofapnea of prematurity. Pediatrics. 2002 Apr;109(4):718-9; author reply 718-9.1132. Gannon BA. Theophylline or caffeine: which is best for apnea of prematurity? Neonatal Netw. 2000Dec;19(8):33-6.1133. Hascoet JM, Hamon I, Boutroy MJ. Risks and benefits of therapies for apnoea in premature infants.Drug Saf. 2000 Nov;23(5):363-79.1134. Henderson-Smart DJ, Osborn DA. Kinesthetic stimulation for preventing apnea in preterm infants.Cochrane Database Syst Rev. 2002;(2):CD000373.1135. Henderson-Smart DJ, Steer PA. Doxapram treatment for apnea in preterm infants. Cochrane DatabaseSyst Rev. 2001;(4):CD000074.1136. Henderson-Smart DJ, Steer P. Doxapram versus methylxanthine for apnea in preterm infants. CochraneDatabase Syst Rev. 2000;(4):CD000075.1137. Henderson-Smart DJ, Steer P. Methylxanthine treatment for apnea in preterm infants. Cochrane DatabaseSyst Rev. 2001;(3):CD000140.MANUAL CLÍNICO AIEPI NEONATAL 156